Increased blood levels of PTH, resulting from decreased activated vitamin D level or accumulation of phosphorus, have been found in patients with CKD. Subsequently, the following changes are known to occur.
1)Changes in bone metabolism associated with activation of PTH receptor signaling pathway
2)Changes in circulating bone metabolism markers
3)Changes in bone density/quality
4)Increased incidence of bone fracture
Daiichi Sankyo aims at creating a novel drug for CKD-MBD focusing on PTH signal regulation with efficient development process driven by markers that respond to PTH signals. The client has decided to seek a partner to develop an in silico model of CKD-MBD incorporating biomarkers that change in response to PTH signals, including bone metabolism markers, bone density, bone quality and fracture risk, and to identify markers (a group of markers) that can be used as a surrogate of PTH signal alteration.